Literature DB >> 2533503

Characterization of the IL-2-receptor on rheumatoid arthritis synovial fluid T cells.

M J Dauphinée1, H Dang, E Flescher, K Wilson-Burris, D Galarza, K Hempel, N Talal.   

Abstract

We studied the hypoproliferative response of synovial fluid (SF) T cells in rheumatoid arthritis (RA) using a mitogenic monoclonal antibody (MoAb) specific for the T-cell antigen receptor-associated CD3 complex. RASF T cells are defective in their proliferative response and in the induction of the Tac (p55) component of the IL-2-receptor (IL-2-R) when stimulated with anti-CD3 monoclonal antibody (MoAb). However, fresh RASF T cells bear demonstrable IL-2-R in cross-linking experiments which are not seen in unstimulated peripheral blood (PB). These receptors are functional since RASF T cells proliferate in response to recombinant IL-2 (rIL-2) better than fresh PB T cells from either normal or RA patients. Scatchard analysis indicates increased (4-fold) numbers of high affinity IL-2-R on (phytohaemagglutinin) PHA-activated RASF T cells as compared with comparably activated RAPB T cells. Phorbol myristate acetate (PMA) induces Tac antigen expression in RASF but does not lead to proliferation. The hyporesponsiveness of RASF T cells does not appear to result from lack of IL-2-R, lack of IL-2-R inducibility, or proliferative potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533503     DOI: 10.1016/0896-8411(89)90007-3

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  2 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease.

Authors:  Duojia Cao; Ronald van Vollenhoven; Lars Klareskog; Christina Trollmo; Vivianne Malmström
Journal:  Arthritis Res Ther       Date:  2004-06-07       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.